Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk.
Raviv Pryluk
Advertisement
Raviv Pryluk is Co-founder and CEO of PhaseV, a leader in AI/ML for clinical development. Prior to his tenure at PhaseV, he held integral roles in operations and data analytics at Immunai, a biotechnology company specializing in the mapping and reprogramming of immunology using machine learning and software engineering. Raviv holds a MSc in aerospace, aeronautical, and astronautical engineering from Technion - Israel Institute of Technology and a Ph.D. in neurobiology and neurosciences from the Weizmann Institute of Science in Rehovot, Israel.
Articles by Raviv Pryluk
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
3
The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma
4
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
5